Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

In Brief: Zeneca Diagnostics/Oncotech

This article was originally published in The Gray Sheet

  • News

Executive Summary

Zeneca Diagnostics/Oncotech: Joint research agreement aims to develop "novel cancer tests" to assist physicians in choosing best treatment options for patients with prostate cancer. Zeneca will supply Oncotech with genetic test reagents to evaluate tissues from cancer patients. Companies will seek to clarify why some prostate cancer patients respond better than others to identical treatment...

Table

View full table

Tags:
Latest Headlines

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

EU: Good News For IVDs And For Future Transparency Of Medtech Compliance

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

See All
UsernamePublicRestriction

Register

MT007826

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By